These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31892329)

  • 21. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study.
    Zang RY; Li ZT; Zhang ZY; Cai SM
    Int J Gynecol Cancer; 2003; 13(4):419-27. PubMed ID: 12911717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
    So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
    J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Plett H; Filippova OT; Garbi A; Kommoss S; Rosendahl M; Langstraat C; Phadnis S; Muallem MZ; Baert T; Chi DS; Aletti GD; Taran FA; Ramspott JP; Zivanovic O; du Bois A; Sonoda Y; Gardner G; Traut A; Roche KL; Harter P
    Gynecol Oncol; 2020 Nov; 159(2):434-441. PubMed ID: 32919778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.
    Chao WT; Chien CH; Lai CR; Wu HJ; Chuang CM
    Cancer Control; 2019; 26(1):1073274819863778. PubMed ID: 31343898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Ehmann S; Lam C; Zhou Q; Iasonos A; Grisham RN; Tew WP; O'Cearbhaill RE; Long Roche K; Zivanovic O; Sonoda Y; Chi DS; Gardner GJ
    Gynecol Oncol; 2024 Jul; 186():104-109. PubMed ID: 38640773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-interval to adjuvant chemotherapy and postoperative management after upper abdominal surgical procedures in advanced ovarian cancer.
    Joneborg U; Palsdottir K; Farm E; Johansson H; Salehi S
    Eur J Surg Oncol; 2021 Feb; 47(2):353-359. PubMed ID: 32778486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
    Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
    Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
    J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
    Petrillo M; Zucchetti M; Cianci S; Morosi L; Ronsini C; Colombo A; D'Incalci M; Scambia G; Fagotti A
    J Gynecol Oncol; 2019 Jul; 30(4):e59. PubMed ID: 31074245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
    Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
    Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
    Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
    Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.